Clinical Trial News & Results
This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.
Baxdrostat Demonstrated Statistically Significant and Clinically Meaningful Reduction in Systolic Blood Pressure in Patients with Hard-to-Control Hypertension in the BaxHTN Phase III Trial
30 August 2025 -- Positive full results from the BaxHTN Phase III trial showed baxdrostat demonstrated a statistically significant and clinically meaningful r...
Regeneron Announces Positive Results from Phase 3 Trial of Cemdisiran in Generalized Myasthenia Gravis
TARRYTOWN, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the primary and key secondary endpoints...
Lilly's Oral GLP-1, Orforglipron, is Successful in Third Phase 3 Trial, Triggering Global Regulatory Submissions This Year for the Treatment of Obesity
INDIANAPOLIS, Aug. 26, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ATTAIN-2 trial...
Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
NEWARK, CA / ACCESS Newswire / August 25, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or "the Company") announced today that rusfertide, a potential...
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine Ixchiq In the U.S.
Saint Herblain (France), August 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United...
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the...
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)
GAITHERSBURG, Md., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based...
FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results
PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on...
Novo Nordisk Lowers Cost of Ozempic to $499 per Month for Self-Paying Patients
PLAINSBORO, N.J., Aug. 18, 2025 /PRNewswire/ -- Novo Nordisk announced the launch of a new offer that enables self-paying, eligible, type 2 diabetes patients...
Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Redmond, WA and Princeton, NJ – August 18, 2025 – SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb...
Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer
BASKING RIDGE, NJ AND RAHWAY, NJ, August 18, 2025 – Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy Designation (BTD) by the U.S...
NIH Scientists Lay Foundation for Potential Gene-Editing Therapy for Late-Onset Tay-Sachs
August 15, 2025 -- Scientists at the National Institutes of Health (NIH) successfully reduced the severity of late-onset Tay-Sachs (LOTS) disease in human cell...
Halda Therapeutics Receives FDA Fast Track Designation for HLD-0915 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NEW HAVEN, CT, August 14, 2025 — Halda Therapeutics, a clinical-stage biotechnology company developing a novel class of therapies called RIPTAC&trade...
Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
CAMBRIDGE, Mass., August 13, 2025 – Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for...
Two-Dose Dalbavancin Therapy for Staphylococcus Aureus Bloodstream Infections on Par with Standard Treatment
August 13, 2025 -- A National Institutes of Health (NIH)-supported clinical trial has found that the outcome of treating complicated Staphylococcus aureus...
Novartis Ianalumab Phase III Trial Meets Primary Endpoint in ITP, Demonstrating Statistically Significant Improvement in Time to Treatment Failure
Basel, August 12, 2025 – Novartis today announced positive top-line results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in...
Novartis Announces Both Ianalumab Phase III Clinical Trials Met Primary Endpoint in Patients with Sjögren’s Disease
Basel, August 11, 2025 – Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults with active...
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
CAMBRIDGE, Mass. and BEDFORD, Mass., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology...
Sebela Pharmaceuticals Announces Successful Completion of Phase 3 TRIUMpH Program of Tegoprazan in GERD with Positive 24-Week Maintenance Phase Results
BRAINTREE, Mass., Aug. 7, 2025 /PRNewswire/ -- Braintree Laboratories, a part of Sebela Pharmaceuticals® and a leading manufacturer of gastroenterology...
Boehringer and Click Therapeutics’ Investigational Prescription Digital Therapeutic CT-155 Meets Primary Endpoint in CONVOKE Study for Negative Symptoms in Schizophrenia
Ingelheim, Germany / Ridgefield, Connecticut / New York, New York, Thu, August 7, 2025 -- Boehringer Ingelheim and Click Therapeutics today announced that the...
Clinical trial results archive
- 2025
- January, February, March, April, May, June, July, August
- 2024
- January, February, March, April, May, June, July, August, September, October, November, December
- 2023
- January, February, March, April, May, June, July, August, September, October, November, December
- 2022
- January, February, March, April, May, June, July, August, September, October, November, December
- 2021
- January, February, March, April, May, June, July, August, September, October, November, December
- 2020
- January, February, March, April, May, June, July, August, September, October, November, December
- 2019
- January, February, March, April, May, June, July, August, September, October, November, December
- 2018
- January, February, March, April, May, June, July, August, September, October, November, December
- 2017
- May, June, July, August, September, October, November, December
- 2016
- October
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.